Characteristics of reovirus-mediated chemoimmunotherapy of murine L1210 leukemia.
We have previously demonstrated the ability of reovirus to function synergistically with chemotherapy in the treatment of murine EL-4 lymphoma. This study characterizes this treatment regimen in the therapy of L1210 leukemia. Animals with an estimated tumor burden of 10(7) cells were treated with 9 mg/kg 1,3-bis(2-chloroethyl)-1-nitrosourea. Reovirus type 3, which had been quantitated either by particles or plaque-forming units (pfu), was administered 48 h after chemotherapy. Complete remission of tumor was observed in 80% of the animals which received either 10(11) particles or 10(9) pfu of reovirus. Cured animals were resistant to challenge with homologous tumor, but were susceptible to challenge with heterologous tumor. Reovirus undergoes limited replication at the tumor site, and virus-specific antibody appears only after disappearance of reovirus-infected cells and virus from the ascites fluid. Reovirus appears to function therapeutically by inducing a tumor-specific cytolytic immune response.
Bryson
J S
JS
Department of Microbiology, Miami University, Oxford, Ohio 45056.
Cox
D C
DC
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D002330:Carmustine / Q000008:administration & dosage / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D004334:Drug Administration Schedule; D007167:Immunotherapy / Q000379:methods*; D007939:Leukemia L1210 / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009500:Neutralization Tests; D012087:Reoviridae / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*
D000914:Antibodies, Viral; D014765:Viral Vaccines; D002330:Carmustine